Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1998-01-13
1999-09-14
MacMillan, Keith D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
A61K 3113
Patent
active
059523891
ABSTRACT:
Disclosed is a method for treating a hyperkinetic movement disorder comprising the steps of selecting a first at least one pharmacologically active agent that acts as a GABA-receptor agonist and a second at least one pharmacologically active agent that acts as a NMDA-type glutamate receptor antagonist, and administering the first and second agents at effective and non-toxic dosages.
REFERENCES:
patent: 4122193 (1978-10-01), Scherm et al.
patent: 4233229 (1980-11-01), Chakrabarti
patent: 4355043 (1982-10-01), Durlach
patent: 5061703 (1991-10-01), Bormann et al.
patent: 5262162 (1993-11-01), Bormann et al.
patent: 5382601 (1995-01-01), Nurnberg et al.
patent: 5455279 (1995-10-01), Lipton
patent: 5614560 (1997-03-01), Lipton
Andrew, "Clinical Relationship of Extrapyramidal Symptoms and Tardive Dyskinesia", Can. J. Psych., 39:576-580, 1994.
Bezchilbynk-Butler et al., "Antiparkinsonian Drugs in the Treatment of Neuroleptic-Induced Extrapyramidal Symptoms", Can. J. Psych., 39:74-84, 1994.
Boumans et al., "Is the Social Acceptability of Psychiatric Patients Decreased by Orofacial Dyskinesia?", Schizo Bull, 20:339-344, 1994.
Buchel et al., "Oral Tardive Dyskinesia: Validation of a Measuring Device Using Digital Image Processing", Psychopharmacology--Berl, 117:162-165, 1995.
Chakos et al., "Incidence and Correlates of Tardive Dyskinesia in First Episode of Schizophrenia", Arch Gen Psychiatry, 53:313-319, 1996.
Deckes et al., "Amantadine Hydrochloride Treatment of Tardive Dyskinesia", Oct. 7, New England J. Med, 285:860, 1971.
Delfs et al., "Expression of Glutamic Acid Decarboxylase mRNA in Striatum and Pallidum in an Animal Model of Tardive Dyskinesia", Exp. Neurol, 133:175-188, 1995.
Dimpfel, "Effects of Memantine on Synaptic Transmission in the Hippocampus in Vitro", Arzneimittelforschung, 45:1-5, 1995.
Erdo et al., "Memantine is Highly Potent in Protecting Cortical Cultures against Excitotoxic Cell Death Evoked by Glutamate and N-Methyl-D-Aspartate", Eur. J. Pharmacol, 198:215-217, 1991.
Gao et al., "Taigabine Inhibits Haloperidol-Induced Oral Dyskinesias in Rats", J. Neural Transmission, 95:63-69, 1994.
Hayashi et al., "Prevalence of and Risk Factors for Respiratory Dyskinesia", Clin. Neuropharmacol, 19:390-395, 1996.
Imamura et al., "Improved Preseveration with Amantadine", Abstract, No-To-Shinkei, 46:556-562, 1994.
Jeste et al., "Risk of Tardive Dyskinesia in Older Patients. A Prospective Longitudinal Study of 266 Outpatients", Arch Gen Psychiatry, 52:756-765, 1995.
Keilhoff et al., "Memantine Prevents Quinolinic Acid-Induced Hippocampal Damage", Eur. J. Pharmacol, 219:451-454, 1992.
Kornhuber et al., "New Therapeutic Possibilities with Low-Affinity NMDA Receptor Antagonists", Abstract, Nervenarzt, 67:77-82, 1996.
Lam et al., Vitamin E in the Treatment of Tardive Dyskinesia: A Replication Study, J. Ner. Ment Dis, 182:113-114, 1994.
Latimer, "Tardive Dyskinesia: A Review", Abstract, Can J. Psych, 40:S49-54, 1995.
Lohr et al., "A Double-Blind Placebo-Controlled Study of Vitamin E Treatment of Tardive Dyskinesia", J. Clin. Psychiatry, 57:167-173, 1996.
Muller et al., "Noncompetitive NMDA Receptor Antagonists with Fast Open-Channel Blocking Kinetics and Strong Voltage-Dependency as Potential Therapeutic Agents for Alzheimer's Dementia", Pharmacopsychiatry, 28:113-124, 1995.
Pahl et al., "Positron-Emission Tomography in Tardive Dyskinesia", J. Neuropsych Clin. Neurosci, 7:457-465, 1995.
Raja, "The Treatment of Tardive Dyskinesia", Abstract, Schweiz Arch Neurol Psychaitr, 47:13-18, 1996.
Sachdev et al., "Negative Symptoms, Cognitive Dysfunction, Tardive Akathisia and Tardive Dyskinesia", Acta Psychiatr Scand, 93:451-459, 1996.
Sano et al., "A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease", The New England Journal of Medicine, vol. 336, No. 17, pp. 1216-1247, Apr. 24, 1997.
Schultz et al., "Neuroprotective Strategies for Treatment of Lesions Produced by Mitochondrial Toxins: Implications for Neurodegenerative Diseases", Neuroscience, 71:1043-1048, 1996.
Silver et al., "No Difference in the Effect of Biperiden and Amatadine on Parkinsonian- and Tardive Dyskinesia-type Involuntary Movements: A Double-Blind Crossover, Placebo-Controlled Study in Medicated Chronic Schizophrenic Patients", Abstract, J. Clin. Psychiatry, 56:167-170, 1995.
Stoessl, "Effects of Ethanol in a Putative Rodent Model of Tardive Dyskinesia", Pharmacol Biochem Behav, 54:541-546, 1996.
Swartz, "Tardive Psychopathology", Neuropsychobiology, 43:115-119, 1995.
Tirelli et al., "Differential Effects of Direct and Indirect Dopamine Agonists on the Induction of Gnawing in C57B1/6J Mice", J. Pharmacol Exp. Ther., 273:7-15, 1995.
Vale et al., "Amantadine ofr Dyskinesia Tarda", New Eng. J. Med., 284:673, 1971.
Van-Rekum et al., "N of 1 Study: Amantadine for the Amotivational Syndrome in a Patient with Traumatic Brain Injury", Brian Inj. 9:49-53, 1995.
Waddington et al., "Cognitive Dysfunction in Chronic Schizophrenia Followed Prospectively Over 10 Years and Its Longitudinal Relationship to the Emergence of Tardive Dyskinesia", Psychol Med, 26:681-688, 1996.
Wenk et al., "MK-801, Memantine and Amantadine Show Neuroprotective Activity in the Nucleus Baslis Magnocellularis", Eur. J. Pharmacol, 293:267-270, 1995.
Database Chemical Abstracts on STN, 1979:483912, Pycock et al, "Dopamine-dependent hyperactivity in the rat following manipulation of GABA mechanisms in the region of the nucleus accumbens", J. Neural Transm. Jan. 1979, 45(1), 17-33.
MacMillan Keith D.
Synchroneuron
LandOfFree
Methods of treating tardive dyskinesia and other movement disord does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating tardive dyskinesia and other movement disord, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating tardive dyskinesia and other movement disord will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1510320